What did Oppenheimer change in its CTMX analyst rating on March 16, 2026?

Oppenheimer **maintained** an Outperform rating and raised the price target to **$12** on March 16, 2026. The action keeps a positive outlook while signaling expectations for improved trial or commercial progress.

How should investors interpret a maintained Outperform in CTMX analyst rating?

A maintained Outperform means the analyst keeps a favorable view but did not move to a higher rating. It implies confidence in upside from catalysts, with a need for upcoming data to justify the higher target.

Does the CTMX analyst rating change affect the stock immediately?

Not always. The maintained Outperform coincided with a reported **-13.07% (-$1.01)** move. Market reaction depends on context, volume, and other news such as trial updates or broader biotech sentiment.

What is Meyka AI’s current grade for CTMX and what does it include?

Meyka AI rates CTMX with a grade of **B+**. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are not guarantees and we are not financial advisors.

Analyst Ratings

Oppenheimer Maintains Outperform on CytomX Therapeutics (CTMX) March 2026

ByHuzaifa Zahoor March 17, 2026March 17, 2026

Oppenheimer maintained an Outperform rating on CytomX Therapeutics, Inc. (CTMX) on March 16, 2026. The CTMX analyst rating note also raised the price target to $12, signaling continued confidence in CytomX’s pipeline and late-stage plans. Oppenheimer’s action follows recent clinical updates and places emphasis on Varseta-M registrational planning. The update arrived alongside a reported -13.07% price move of -$1.01 from the referenced level, and the company’s market cap stands at $1,143,686,250.